Twin Capital Management Inc. lowered its holdings in Eli Lilly And Co (NYSE:LLY) by 38.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 70,510 shares of the company’s stock after selling 44,340 shares during the quarter. Twin Capital Management Inc.’s holdings in Eli Lilly And Co were worth $7,812,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. FMR LLC raised its stake in shares of Eli Lilly And Co by 1.7% during the 1st quarter. FMR LLC now owns 13,916,001 shares of the company’s stock worth $1,805,741,000 after purchasing an additional 228,920 shares during the period. Fisher Asset Management LLC grew its holdings in shares of Eli Lilly And Co by 4.9% during the second quarter. Fisher Asset Management LLC now owns 4,127,933 shares of the company’s stock worth $457,334,000 after purchasing an additional 192,702 shares in the last quarter. California Public Employees Retirement System lifted its position in Eli Lilly And Co by 8.1% in the 1st quarter. California Public Employees Retirement System now owns 3,162,898 shares of the company’s stock worth $410,418,000 after buying an additional 238,198 shares during the last quarter. Parametric Portfolio Associates LLC lifted its position in Eli Lilly And Co by 5.3% in the 1st quarter. Parametric Portfolio Associates LLC now owns 3,080,350 shares of the company’s stock worth $399,706,000 after buying an additional 156,321 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its position in Eli Lilly And Co by 1.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,396,949 shares of the company’s stock worth $311,030,000 after buying an additional 41,525 shares during the last quarter. 79.48% of the stock is owned by institutional investors and hedge funds.
A number of analysts recently weighed in on LLY shares. Cantor Fitzgerald restated a “buy” rating and issued a $143.00 target price on shares of Eli Lilly And Co in a research report on Tuesday, April 30th. Edward Jones upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 price objective for the company in a research report on Tuesday, April 23rd. BMO Capital Markets boosted their price objective on Eli Lilly And Co from $130.00 to $133.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. Zacks Investment Research downgraded Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, May 21st. Finally, ValuEngine downgraded Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Friday, June 28th. Nine research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $123.49.
Shares of Eli Lilly And Co stock traded down $0.20 during midday trading on Thursday, reaching $110.09. 108,123 shares of the company’s stock traded hands, compared to its average volume of 3,974,435. The company has a debt-to-equity ratio of 4.98, a quick ratio of 0.87 and a current ratio of 1.13. The company has a market capitalization of $109.60 billion, a P/E ratio of 19.90, a PEG ratio of 2.01 and a beta of 0.19. The company’s 50 day moving average is $110.66. Eli Lilly And Co has a 12 month low of $102.08 and a 12 month high of $132.13.
Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Tuesday, July 30th. The company reported $1.50 EPS for the quarter, beating analysts’ consensus estimates of $1.45 by $0.05. The company had revenue of $5.64 billion during the quarter, compared to the consensus estimate of $5.59 billion. Eli Lilly And Co had a return on equity of 70.86% and a net margin of 33.76%. The firm’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.48 earnings per share. Research analysts anticipate that Eli Lilly And Co will post 5.72 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be issued a dividend of $0.645 per share. The ex-dividend date of this dividend is Wednesday, August 14th. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.34%. Eli Lilly And Co’s dividend payout ratio is presently 46.49%.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Recommended Story: How To Calculate Debt-to-Equity Ratio
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.